GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (FRA:A28A) » Definitions » Long-Term Capital Lease Obligation

Affimed NV (FRA:A28A) Long-Term Capital Lease Obligation : €6.66 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Long-Term Capital Lease Obligation?

Affimed NV's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.66 Mil.

Affimed NV's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 (€0.12 Mil) to Sep. 2023 (€6.87 Mil) but then declined from Sep. 2023 (€6.87 Mil) to Dec. 2023 (€6.66 Mil).

Affimed NV's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€0.37 Mil) to Dec. 2022 (€0.18 Mil) but then increased from Dec. 2022 (€0.18 Mil) to Dec. 2023 (€6.66 Mil).


Affimed NV Long-Term Capital Lease Obligation Historical Data

The historical data trend for Affimed NV's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Long-Term Capital Lease Obligation Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.48 0.37 0.18 6.66

Affimed NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.16 0.12 6.87 6.66

Affimed NV  (FRA:A28A) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Affimed NV Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Affimed NV's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Affimed NV (FRA:A28A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (FRA:A28A) » Definitions » Long-Term Capital Lease Obligation
Traded in Other Exchanges
Address
Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Affimed NV (FRA:A28A) Headlines

No Headlines